1
|
Konda SM, Woodward JA. A Comprehensive Review of Use of Neurotoxins for Periocular Rejuvenation. Int Ophthalmol Clin 2024; 64:51-59. [PMID: 38910505 DOI: 10.1097/iio.0000000000000528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/25/2024]
|
2
|
Taylor-Barnes K. Real-World Patient Experience With PrabotulinumtoxinA in the United Kingdom: A Single-Center Survey and Analysis of 254 Patients. Aesthet Surg J Open Forum 2024; 6:ojae013. [PMID: 38828475 PMCID: PMC11140816 DOI: 10.1093/asjof/ojae013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2024] Open
Abstract
Background Botulinum toxin Type A (BoNT-A) injection is the most widely performed nonsurgical cosmetic procedure in the United Kingdom. PrabotulinumtoxinA is a new BoNT-A, recently licensed in the United Kingdom, for treating moderate-to-severe glabellar lines in adults under 65. Although clinical trials have established safety and efficacy, real-world data can help clinicians translate study findings into practice and support prabotulinumtoxinA use in a more diverse patient population. Objectives To understand the real-world patient experience and patient perceptions of prabotulinumtoxinA performance for treatment of the glabellar region. Methods In this single-center survey study, a single injector administered prabotulinumtoxinA for the treatment of glabellar lines to real-world patients presenting for BoNT-A treatment. Two weeks later, patients received surveys asking about their experience through email. There were no incentives for participation. Responses returned within 5 weeks of treatment were included. Results From February to June 2023, 457 patients received prabotulinumtoxinA injections for glabellar line treatment. Survey response rate was 56% (254/457 patients). For most patients, treatment onset was 2 to 3 days following injection and peak response occurred after 7 to 10 days. Adverse effects were minimal, with 67% of patients experiencing none. Among survey respondents, 83% rated their treatment positively (5-point satisfaction scale), and 72% would choose prabotulinumtoxinA again. Conclusions These data support safety and effectiveness of prabotulinumtoxinA in a diverse, real-world population, and confirm patient satisfaction among experienced BoNT-A patients, as well as suggest a rapid time to onset and peak effect. Level of Evidence 4
Collapse
Affiliation(s)
- Kathryn Taylor-Barnes
- Corresponding Author: Dr Kathryn Taylor-Barnes, 16 Bridle Lane, St Margarets, Twickenham, London TW1 3EG, UK. E-mail:
| |
Collapse
|
3
|
Philipp-Dormston WG, De Boulle K, Gronovich Y, Lowe N, Sayed K, Sykianakis D, Tuncer S. The Patient Journey in Facial Aesthetics: Findings from a European Consensus Meeting on Improving the Quality of Life for Patients Receiving Botulinum Toxin Injections. Clin Cosmet Investig Dermatol 2024; 17:329-337. [PMID: 38327550 PMCID: PMC10847668 DOI: 10.2147/ccid.s446891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 01/25/2024] [Indexed: 02/09/2024]
Abstract
Purpose Successful treatment of facial lines with botulinum toxin is largely dependent on patient satisfaction; thus, a structured treatment journey that uses patient-reported outcomes (PROs) is helpful for maximizing botulinum toxin results. To develop a patient-centric approach for botulinum toxin injections in facial aesthetics, a group of clinicians met to provide opinions on an optimal treatment journey that uses PROs to quantify treatment benefits on patient quality of life. Patients and Methods A multidisciplinary panel of 9 clinicians with expertise in facial aesthetic procedures convened for an advisory board that was preceded by and followed up with a structured, multistep consensus discussion. Based on current literature, the panel's expertise, structured questions, and group discussion, panelists assessed, reconciled, and agreed upon on a patient journey for botulinum toxin treatment in facial aesthetics. Results Panelists agreed that an optimal patient journey includes screening, assessment, treatment, posttreatment, and follow-up visits. A compact, easy-to-complete, and digital PRO questionnaire should be provided before the visit. During screening, thorough assessments are integral for a successful patient journey because they provide an opportunity to understand treatment goals, address patient concerns, discuss risks and benefits, obtain medication lists/medical history, and take pretreatment photographs. Treatment strategies should include discussing and educating on the approach/choice of botulinum toxin and ensuring patients are comfortable. Posttreatment, clinicians should request intense muscle movements to enhance product uptake and be available to address patient concerns. Finally, during follow-up, PRO questionnaires can be provided to gauge patient satisfaction with treatment, and pretreatment photographs can be provided to allow patients to track their progression. Follow-ups should be scheduled with new patients or those reporting low satisfaction. Conclusion Establishing a relationship, being aware of the patient's goals, and developing an individualized care plan allows for a structured, patient-centered treatment journey that promotes positive aesthetic outcomes.
Collapse
Affiliation(s)
| | | | - Yoav Gronovich
- Department of Plastic and Reconstructive Surgery, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Nick Lowe
- University of Manchester, Manchester, UK
- University of California, Los Angeles School of Medicine, Los Angeles, CA, USA
| | - Karim Sayed
- Nomi Oslo Clinic, Oslo, Norway
- Ouronyx Clinic, London, UK
- University of South-Eastern Norway, Drammen, Norway
| | | | | |
Collapse
|
4
|
Hedayat K, Ehsani AH. A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines. Aesthetic Plast Surg 2024; 48:324-332. [PMID: 38233684 DOI: 10.1007/s00266-023-03766-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 11/17/2023] [Indexed: 01/19/2024]
Abstract
BACKGROUND Botulinum toxin type A is a widely used treatment of facial wrinkles. The objective of this study was to compare the efficacy and safety of a new botulinum toxin type A (Masport [abobotulinum toxin A], MasoonDarou Co) with DYSPORT® for the treatment of glabellar lines. METHODS 262 subjects with moderate-to-severe glabellar lines received either a fixed dose of 50 units of MASPORT® or DYSPORT® (Ipsen Company, England). Subjects were followed up at 14, 30, 60, 90 and 120 days after injection. Efficacy was assessed by investigator at maximum frown and rest and also by Subject Global Assessment of Change (SGA). The responders were defined as persons with +2 grade improvement from baseline for both investigator and patient assessment. The occurrence and duration of adverse effects were recorded up throughout the study. RESULTS According to the investigator evaluations, the responder rate at maximum frown were 94.5% for MASPORT and 95.6% for DYSPORT group on day 30 and at rest were 85.45% and 85.68% for MASPORT and DYSPORT group, respectively. According to the subject self-assessment, the proportion of responders in MASPORT group at day 30 was 95.28% versus 97.04% for DYSPORT group. No serious drug related adverse effect was recorded in either study groups, and the rates of adverse effects were similar for both groups. CONCLUSION Abobotulinum toxin A [MASPORT] is equally safe and effective as commercial product [DYSPORT] for the treatment of glabellar lines with the dose of 50 units, up to 120 days. LEVEL OF EVIDENCE I This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Collapse
Affiliation(s)
| | - Amir H Ehsani
- Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
5
|
Jouni H, Jouffe L, Tancrede‐Bohin E, André P, Benamor S, Cabotin P, Chen J, Chen Z, Conceiçao K, Dlova N, Figoni‐Laugel C, Han X, Li D, Pansé I, Pavlovic‐Ganascia M, Harvey V, Ly F, Niverd‐Rondelé S, Khoza N, Petit A, Roux M, Shi Y, Tardy‐Bastide I, Vashi N, Wang S, Wang Y, Wu J, Xu N, Yan Y, Gomes C, Raynaud E. Predicting the evolution of clinical skin aging in a multi-ethnic population: Developing causal Bayesian networks using dermatological expertise. Skin Res Technol 2024; 30:e13602. [PMID: 38348764 PMCID: PMC10862181 DOI: 10.1111/srt.13602] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 12/20/2023] [Indexed: 02/15/2024]
Abstract
INTRODUCTION Software to predict the impact of aging on physical appearance is increasingly popular. But it does not consider the complex interplay of factors that contribute to skin aging. OBJECTIVES To predict the +15-year progression of clinical signs of skin aging by developing Causal Bayesian Belief Networks (CBBNs) using expert knowledge from dermatologists. MATERIAL AND METHODS Structures and conditional probability distributions were elicited worldwide from dermatologists with experience of at least 15 years in aesthetics. CBBN models were built for all phototypes and for ages ranging from 18 to 65 years, focusing on wrinkles, pigmentary heterogeneity and facial ptosis. Models were also evaluated by a group of independent dermatologists ensuring the quality of prediction of the cumulative effects of extrinsic and intrinsic skin aging factors, especially the distribution of scores for clinical signs 15 years after the initial assessment. RESULTS For easiness, only models on African skins are presented in this paper. The forehead wrinkle evolution model has been detailed. Specific atlas and extrinsic factors of facial aging were used for this skin type. But the prediction method has been validated for all phototypes, and for all clinical signs of facial aging. CONCLUSION This method proposes a skin aging model that predicts the aging process for each clinical sign, considering endogenous and exogenous factors. It simulates aging curves according to lifestyle. It can be used as a preventive tool and could be coupled with a generative AI algorithm to visualize aging and, potentially, other skin conditions, using appropriate images.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jin Chen
- The First Affiliated Hospital of Chongqing Medical UniversityChongqingChina
| | - Zekai Chen
- Huizhou First Maternal and Child Health HospitalHuizhouChina
| | | | - Ncoza Dlova
- Dermatology DepartmentNelson R Mandela School of MedicineUniversity of KwaZulu‐NatalDurbanSouth Africa
| | | | - Xianwei Han
- Shenyang Seventh People's HospitalShanghaiChina
| | - Dongni Li
- Guangdong Second People's HospitalGuangdongChina
| | | | | | - Valerie Harvey
- Hampton Roads Center for DermatologyNewport NewsVirginiaSkin of Color Research InstituteHampton UniversityHamptonVirginiaUSA
| | - Fatimata Ly
- Dermatology and VenerologyCheikh Anta Diop UniversityDakarSenegal
| | | | | | - Antoine Petit
- Dermatology and Venereology DepartmentSaint‐Louis HospitalParis Cité UniversityParisFrance
| | | | - Yu Shi
- Shanghai Dermatology HospitalShanghaiChina
| | | | - Neelam Vashi
- Dermatology DepartmentBoston University Chobanian & Avedisian School of MedicineBostonUSA
| | - Shanqing Wang
- Dermatology DepartmentRuijin Hospital Shanghai Jiao Tong University School of MedicineShanghaiChina
| | - Youli Wang
- Zhuji Traditional Chinese Medicine HospitalZhejiangChina
| | - Jun Wu
- L'Oréal Research and InnovationShanghaiChina
| | - Nan Xu
- Shanghai Oriental HospitalShanghaiChina
| | - Yuehua Yan
- Fudan University Pudong HospitalShanghaiChina
| | | | - Edouard Raynaud
- L'Oreal Research and InnovationClichyFrance
- CRB St Louis HospitalParisFrance
| |
Collapse
|
6
|
Mussarat A, Mustafa MS, Azam ST, Nafees uddin MM, Nasrullah RMU, Siddiq MA. DAXI (DaxibotulinumtoxinA) - An Innovative Approach for Frown Lines. Int J Gen Med 2023; 16:1267-1269. [PMID: 37065981 PMCID: PMC10103897 DOI: 10.2147/ijgm.s406563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 04/02/2023] [Indexed: 04/18/2023] Open
Abstract
Glabellar frown lines, also known as worry lines, are a common sign of aging. The current treatment option for glabellar lines is subjective and ranges from economical anti-wrinkle creams and skin resurfacing techniques such as microdermabrasion and fillers to highly expensive facelifts. Botox® has been the mainstream treatment for decades, but the suggested time between treatments for most toxins is 12-16 weeks, and evidence shows that patients being treated for glabellar lines want longer-lasting results. Recently, on September 16th, the US Food and Drug Administration (FDA) approved the development of daxibotulinumtoxinA (DAXI) for injection based on clinical trials (SAKURA 1, 2, and 3). These encouraging findings followed by FDA approval mean that the need for repeated treatments to sustain the desired outcome has decreased. DAXI could be a reliable and secure choice for reducing the appearance of wrinkles on the face caused by muscle activity, and its long duration has the potential to enhance the treatment of both therapeutic and cosmetic disorders.
Collapse
Affiliation(s)
- Abdullah Mussarat
- Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
| | | | - Syed Talal Azam
- Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
| | | | | | - Mohammad Arham Siddiq
- Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
- Correspondence: Mohammad Arham Siddiq, Department of Medicine, Jinnah Sindh Medical University, Iqbal Shaheed Road, Karachi, Pakistan, Tel +923412127759, Email
| |
Collapse
|
7
|
Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study. Dermatol Surg 2023; 49:60-65. [PMID: 36533798 PMCID: PMC9760460 DOI: 10.1097/dss.0000000000003637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND Simultaneous treatment of moderate-to-severe upper facial lines is reflective of real-world clinical practice. OBJECTIVE To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and lateral canthal (LC) lines. METHODS In this open-label, single-arm Phase 2 study, patients (48 enrolled, 94% completed, follow-up 24-36 weeks) received DAXI 40U (glabellar), 32U (forehead), and 48U (LC) lines. Key efficacy endpoints: percentages of patients achieving none/mild wrinkle severity (investigator-rated) for each upper facial line scale at Week 4. RESULTS At Week 4, most patients achieved none/mild wrinkle severity (investigator-rated): glabellar (96%), forehead (96%), and LC (92%). Median times to loss of none/mild response (investigator- and patient-rated) among all patients were: 24.6 (glabellar), 20.9 (forehead), and 24.9 (LC) weeks; and 25.0, 24.0, and 28.1 weeks, respectively, among Week-4 responders. At Week 4, most patients reported improvements (Global Aesthetic Improvement Scale: 96%-98%) and high satisfaction rates (85%-98%). Five patients experienced treatment-related adverse events: injection-site erythema (3 patients/7 events), facial discomfort (2 patients/2 events), and headache (1 patient/1 event). No patients experienced eyebrow or eyelid ptosis. CONCLUSION Simultaneous treatment of upper facial lines with DAXI was well tolerated and demonstrated high response rates, extended duration, and high patient satisfaction. CLINICAL TRIAL REGISTRY https://clinicaltrials.gov/ct2/show/NCT04259086.
Collapse
|
8
|
Calkin JM, Boudreaux AA, Taylor B. Efficacy and tolerability of a novel skin cream for improving periocular rhytids and dryness. J Cosmet Dermatol 2022; 21:5769-5778. [PMID: 35851986 DOI: 10.1111/jocd.15249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 07/11/2022] [Accepted: 07/15/2022] [Indexed: 12/27/2022]
Abstract
OBJECTIVE A novel topical cream was developed to address the appearance of aging periorbital skin. The goal of this study was to evaluate the efficacy and tolerability of this product (Total Eye® Firm & Repair Cream; Colorescience, Inc., Carlsbad, CA) for improving periorbital wrinkles, dryness, laxity, and dark circles. METHODS This 8-week open-label trial enrolled subjects 35-65 years old seeking periocular rejuvenation (N = 25; 22 female, 3 male). The product was applied each morning and evening after facial cleansing. Study endpoints were changes in Investigator Clinical Grading and Eye Appearance Assessments, Subject Self-assessment Questionnaires, and tolerability after 4 and 8 weeks of treatment. RESULTS Among subjects completing the study (n = 23), all (100%) showed some global improvement at Weeks 4 and 8 and almost half (48%) achieved moderate or marked improvement. Improvements were observed for all parameters and were most pronounced for wrinkles, laxity, and dark circles. Improvements for laxity and dryness were significant by Week 4 and for dark circles by Week 8. At Week 8, subjects agreed or strongly agreed that the product made their eyes feel more hydrated (100%), look and feel healthier (95%), and increased confidence in their eye appearance (91%). The product was well-tolerated. LIMITATIONS Modest number of subjects and open-label study design. CONCLUSION Twice-daily Total Eye® Firm & Repair Cream improved the overall appearance of the periorbital area. The product was well-tolerated and most treated subjects were satisfied with their results. The product is a viable option for treating periorbital wrinkles and laxity and should be considered a safe and effective skincare option.
Collapse
|
9
|
Wu Y, Li C, Garcia J, Baradaran S. Patient-reported Outcomes in Chinese Subjects Treated with OnabotulinumtoxinA for Crow's Feet Lines. THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY 2021; 14:27-31. [PMID: 34976286 PMCID: PMC8711615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
BACKGROUND Crow's feet lines (CFLs) can impact the emotional state, self-perception, and consciousness regarding appearance of patients. OBJECTIVE This study sought to assess patient-reported outcomes after onabotulinumtoxinA treatment for CFLs among Chinese subjects. METHODS A five-month, double-blind, randomized, parallel-group, placebo-controlled Phase III clinical study was conducted including Chinese adults with moderate-to-severe CFLs at maximum smile. Subjects were randomized 3:1 to 24 U of onabotulinumtoxinA or placebo and completed the 11-item Facial Line Outcomes (FLO-11) questionnaire and Facial Line Satisfaction Questionnaire (FLSQ) at baseline; on Days 8, 15, and 30; and monthly thereafter until Day 150. Item-level and/or domain analyses for the FLO-11 and FLSQ were conducted. RESULTS Of 417 treated subjects, 316 received onabotulinumtoxinA and 101 received placebo. For all 10 validated stand-alone FLO-11 items, there was a significantly greater proportion of responders in the onabotulinumtoxinA group versus placebo (P<0.001) at Day 30 that was maintained through Day 150. Significant improvements at Day 30 were reported for all FLSQ items and the FLSQ Follow-up Impact Domain (P≤0.01). CONCLUSION FLO-11 and FLSQ data indicated high satisfaction and significant improvements in appearance-related and emotional impacts through Day 150 in patients treated with onabotulinumtoxinA for moderate-to-severe CFLs in Chinese subjects. TRIAL REGISTRATION ClinicalTrials.gov identifier no. NCT02195687.
Collapse
Affiliation(s)
- Yan Wu
- Dr. Wu is with Peking University First Hospital in Beijing, China. Dr. Li is with the Chinese PLA General Hospital in Beijing, China
- Drs. Garcia and Baradaran are with Allergan Aesthetics, an AbbVie Company, in Irvine, California
| | - Chengxin Li
- Dr. Wu is with Peking University First Hospital in Beijing, China. Dr. Li is with the Chinese PLA General Hospital in Beijing, China
- Drs. Garcia and Baradaran are with Allergan Aesthetics, an AbbVie Company, in Irvine, California
| | - Julia Garcia
- Dr. Wu is with Peking University First Hospital in Beijing, China. Dr. Li is with the Chinese PLA General Hospital in Beijing, China
- Drs. Garcia and Baradaran are with Allergan Aesthetics, an AbbVie Company, in Irvine, California
| | - Sarah Baradaran
- Dr. Wu is with Peking University First Hospital in Beijing, China. Dr. Li is with the Chinese PLA General Hospital in Beijing, China
- Drs. Garcia and Baradaran are with Allergan Aesthetics, an AbbVie Company, in Irvine, California
| |
Collapse
|
10
|
Kaufman-Janette J, Cox SE, Dayan S, Joseph J. Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes? Toxins (Basel) 2021; 13:494. [PMID: 34357966 PMCID: PMC8310242 DOI: 10.3390/toxins13070494] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 07/13/2021] [Accepted: 07/14/2021] [Indexed: 11/16/2022] Open
Abstract
Botulinum toxin serotype-A (BoNT-A) preparations are widely used to improve the appearance of wrinkles. While effective and well tolerated, patients require retreatment over time to re-establish the effects. There is growing interest from patients as to whether higher doses can prolong response without significantly increasing side effects. We reviewed the efficacy and safety evidence for high-dose BoNT-A treatment of glabellar lines, by evaluating high-dose studies published since 2015. Toxins approved for glabellar line treatment in the US or Europe were considered. "High-dose" indicated doses above the licensed dose for each BoNT-A preparation. Five studies met the inclusion criteria and most were randomized, double-blind trials; designs and population sizes varied. Findings suggested that higher-dose BoNT-A treatment is feasible and may improve response duration without increased safety issues. Around 9 months' median duration was achieved with a 2-2.5-fold increase of the abobotulinumtoxinA on-label dose, or with a 5-fold increase in incobotulinumtoxinA dose. A 2-4-fold increase of the onabotulinumtoxinA on-label dose yielded a median duration of around 6 months. Importantly, patient satisfaction and natural look remained with increasing abobotulinumtoxinA doses. While more data are needed, these findings may lead to more effective, individually tailored treatment plans to meet patient expectations.
Collapse
Affiliation(s)
- Joely Kaufman-Janette
- Skin Associates of South Florida, Skin Research Institute, 4425, Ponce De Leon Boulevard, Suite 200, Coral Gables, FL 33146-1871, USA
| | | | | | - John Joseph
- Clinical Testing of Beverly Hills, Encino, CA 91436, USA;
| |
Collapse
|
11
|
Patel V, Lee E, Silberberg MB. Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA Patient-Reported Outcome Guidance. Aesthet Surg J 2020; 40:NP710-NP711. [PMID: 32539077 PMCID: PMC7676452 DOI: 10.1093/asj/sjaa101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|